PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compared to currently approved obesity therapies.

加利福尼亚州帕萨迪纳（商业新闻短讯）--箭头制药公司（NASDAQ:ARWR）今天介绍了临床前数据，并详细介绍了其计划，将两个基于RNAi的下一代候选基因ARO-INHBE和ARO-ALK7推进即将进行的肥胖和代谢性疾病治疗临床研究。在迄今为止的临床前研究中，这些候选人证明了通过一种新的作用机制降低体重和脂肪量的潜力，与目前批准的肥胖疗法相比，这种作用机制可能会改善瘦肌肉的保存。

Arrowhead plans to submit clinical trial applications with regulatory authorities for both programs by the end of 2024 with the goal of initiating clinical studies in volunteers with obesity in early 2025..

箭头计划在2024年底之前向监管机构提交这两个项目的临床试验申请，目标是在2025年初开始对肥胖志愿者进行临床研究。。

“Arrowhead believes that targeting the hepatic expression of the INHBE gene and the production of the Activin E ligand, and the adipose tissue expression of the ALK7 gene and the receptor it encodes, represent promising novel mechanisms to treat obesity and associated metabolic diseases. When studied as mono therapy and in combination with tirzepatide in diet induced obesity mouse models, ARO-INHBE and ARO-ALK7 both resulted in suppression of body weight and fat mass and, importantly, preservation of lean mass leading to improved body composition,” said James Hamilton, M.D., Chief of Discovery and Translational Medicine at Arrowhead.

“Arrowhead认为，靶向INHBE基因的肝脏表达和激活素E配体的产生，以及ALK7基因及其编码受体的脂肪组织表达，代表了治疗肥胖和相关代谢疾病的有希望的新机制。当在饮食诱导的肥胖小鼠模型中作为单一疗法和与替利帕特联合研究时，ARO-INHBE和ARO-ALK7都能抑制体重和脂肪量，重要的是，保持瘦体重，从而改善身体组成，”Arrowhead的发现和转化医学主任詹姆斯·汉密尔顿（JamesHamilton）医学博士说。

“Following the approval and positive clinical impact of new agents for obesity over the last few years, new therapeutic strategies with novel mechanisms of action are emerging that may represent the future in successful treatment and management of patients with obesity and associated diseases. We are in the final stages of preclinical development of ARO-INHBE and ARO-ALK7 and we are eager to engage with regulators by the end of this year to begin clinical studies of these exciting new medicines.”.

“在过去几年中，随着新型肥胖药物的批准和积极的临床影响，新的治疗策略和新的作用机制正在出现，这可能代表肥胖和相关疾病患者成功治疗和管理的未来。我们正处于ARO-INHBE和ARO-ALK7临床前开发的最后阶段，我们渴望在今年年底之前与监管机构合作，开始这些令人兴奋的新药的临床研究。”。

ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. ARO-ALK7 is designed to reduce the adipose expression of Activin receptor-like kinase 7 (ALK7). INHBE and ALK7 are both genetically validated targets with loss of function variants being associated with lower risk of obesity and metabolic diseases, such as type 2 diabetes.

ARO-INHBE旨在降低INHBE基因及其分泌基因产物激活素E的肝脏表达。ARO-ALK7旨在降低激活素受体样激酶7（ALK7）的脂肪表达。INHBE和ALK7都是经过基因验证的靶标，功能丧失变异与肥胖和代谢疾病（如2型糖尿病）的风险较低有关。

Both targets are involved in the same pathway that regulates energy homeostasis in adipose tissue​, with Activin E acting as a circulating ligand and ALK7 as a receptor on adipocytes. Intervening in this pathway with ARO-INHBE and ARO-ALK7 is believed to result in increased lipolysis, and reductions in adipose hypertrophy and dysfunction, visceral adiposity, and insulin resistance..

这两个靶标都参与调节脂肪组织能量稳态的相同途径，激活素E作为循环配体，ALK7作为脂肪细胞上的受体。据信，用ARO-INHBE和ARO-ALK7干预该途径会导致脂解增加，并减少脂肪肥大和功能障碍，内脏肥胖和胰岛素抵抗。。

To learn more about ARO-INHBE and ARO-ALK7, please join Part IV of Arrowhead’s 2024 Summer Series of R&D Webinars, being held today, August 14, 2024, at 2:00 PM ET. The event will feature Arrowhead management and Carel le Roux, M.D., Ph.D., from University College Dublin. The live event and an archived webcast may be accessed on the Events and Presentations page in the Investors section of the Arrowhead website..

要了解有关ARO-INHBE和ARO-ALK7的更多信息，请参加今天2024年8月14日下午2:00举行的箭头2024年夏季系列研发网络研讨会的第四部分。该活动将以箭头管理和都柏林大学学院的Carel le Roux医学博士为特色。现场活动和存档的网络广播可以在箭头网站投资者部分的活动和演示页面上访问。。

About Arrowhead Pharmaceuticals

关于箭头制药

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

箭头制药公司（Arrowhead Pharmaceuticals）通过沉默导致顽固性疾病的基因来开发治疗顽固性疾病的药物。使用广泛的RNA化学组合和有效的递送方式，箭头疗法触发RNA干扰机制，以诱导靶基因的快速，深入和持久的敲低。

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing..

RNA干扰（RNAi）是活细胞中存在的一种机制，可抑制特定基因的表达，从而影响特定蛋白质的产生。Arrowhead基于RNAi的疗法利用了这种基因沉默的自然途径。。

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

欲了解更多信息，请访问www.arrowheadharma.com，或通过X（以前的推特）关注我们@arrowheadharma或LinkedIn。要添加到公司的电子邮件列表并直接接收新闻，请访问http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

私人证券诉讼改革法案下的安全港声明：

This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性声明。除历史信息外，本版本中包含的任何声明都可能被视为前瞻性声明。在不限制上述一般性的情况下，诸如“可能”、“将”、“预期”、“相信”、“预期”、“希望”、“打算”、“计划”、“项目”、“可能”、“估计”、“继续”、“目标”、“预测”或“继续”等词语或其其他变体或类似术语的否定词旨在识别此类前瞻性陈述。

In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.

此外，任何涉及我们未来财务业绩预测、业务趋势、对我们产品线或候选产品的期望（包括预期的监管提交和临床计划结果）、我们与其他公司合作的前景或益处，或未来事件或情况的其他特征的声明都是前瞻性声明。

These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.

这些前瞻性陈述包括但不限于关于我们的临床前研究和临床试验以及我们的研究和开发计划的开始，时间，进展和结果的陈述；我们对合作伙伴关系、许可和/或合作安排以及我们已经达成或将来可能达成的其他战略安排和交易的潜在利益的期望；我们对里程碑、特许权使用费或现有协议下可能应付给第三方或来自第三方的其他付款的信念和期望；以及我们对未来收入、研发费用、资本要求和向第三方付款的估计。

These statements are based u.

这些声明基于美国。

Source: Arrowhead Pharmaceuticals, Inc.

来源：Arrowhead Pharmaceuticals，Inc。